The Weekly Recap 1/2/2026: Biobeat Special Feature

On December 30, 2025, Biobeat Technologies, Ltd. announced the closing of a $50 million Series B equity financing led by new investors Ally Bridge Group, OrbiMed, and Elevage Medical, with participation from a strategic investor. Proceeds from the funding will be used to expand commercialization in the United States.

Origin Story

Biobeat was founded in 2016 with a straightforward but ambitious idea: continuous vital-sign monitoring should not be confined to bulky bedside equipment or invasive procedures.

The company was founded in Israel by Arik Ben Ishay, Johanan May, and Israel Sarussi, bringing together backgrounds in emergency medicine, IoT systems, and advanced optical sensing. The founding insight came from firsthand exposure to acute and remote-care environments, where vital signs were often measured intermittently, manually, or too late to prevent deterioration.

Ben Ishay’s experience as a volunteer paramedic highlighted a recurring problem: clinicians were forced to make decisions based on snapshots of patient data rather than continuous physiological trends. In high-stress or resource-limited settings, that gap could mean delayed intervention.

Rather than improving traditional monitors incrementally, the founders focused on eliminating cuffs, wires, and manual measurements altogether. Sarussi’s decades of work in reflective photoplethysmography (PPG) enabled the team to pursue something many considered impractical at the time: continuous, cuffless blood pressure and vital-sign monitoring using a wearable sensor with wireless connectivity and cloud analytics, allowing data to flow continuously from the patient to clinicians in real time.

That vision reached a major milestone when Biobeat became the first company to receive FDA clearance for a cuffless blood pressure monitoring device based solely on PPG technology. The clearance validated both the technology and the clinical relevance of continuous 24-hour ambulatory blood pressure monitoring (ABPM), especially during nighttime hours.

Today, Biobeat’s wearable chest patches and wrist monitors are used across hospitals, step-down units, and remote patient monitoring programs, reflecting the company’s original belief that better data leads to earlier intervention and better outcomes.

Inside the Innovation

At the core of Biobeat’s technology is its proprietary reflective photoplethysmography sensor. PPG measures changes in blood volume beneath the skin using optical signals, enabling non-invasive monitoring of cardiovascular parameters.

Biobeat applies this technology to cuffless blood pressure measurement, a capability that has historically been difficult to achieve with clinical accuracy. The company’s algorithms translate raw optical signals into continuous blood pressure data validated for diagnosis and treatment of hypertension.

The platform is built around two primary form factors. A disposable chest patch enables continuous ambulatory monitoring during people’s regular daily activities.

Data is transmitted wirelessly to a secure cloud platform. Data is available within 30 seconds after completion of the 24-hour test to clinicians in numerous ways: automatically downloaded directly into an institution’s EPIC® system, sent via PDF and accessed via a dashboard that displays trends and data.

Upon completion of the test, Biobeat’s system is 100% disposable, so nothing needs to be collected from the patient. Moreover, the product is designed to integrate into existing clinical workflows and scale across care settings. The innovation is not limited to the technology itself, but extends to how data is collected, analyzed, and acted upon in real time.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-122026-biobeat-special-feature